- Home
- GBLI vs EBS Comparison
GBLI vs EBS Comparison
Compare GBLI & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | EBS |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.7M | 413.3M |
| IPO Year | 2010 | 2006 |
Fundamental Metrics
Financial Performance| Metric | GBLI | EBS |
|---|---|---|
| Price | $27.22 | $7.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 5.8K | ★ 645.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ 0.29 | 0.07 |
| Revenue | $450,098,000.00 | ★ $742,900,000.00 |
| Revenue This Year | $14.23 | $1.29 |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | ★ $94.83 | $105.86 |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $24.28 | $6.03 |
| 52 Week High | $30.52 | $14.06 |
Technical Indicators
Market Signals| Indicator | GBLI | EBS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.12 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $8.59 |
| Average True Range (ATR) | 0.00 | 0.22 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 34.48 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.